Koshiyama M, Fujii H, Kinezaki M, Yoshida M
Department of Obstetrics and Gynaecology, Tenri Hospital, Tenri, Nara, Japan.
Anticancer Res. 2001 Mar-Apr;21(2A):905-10.
The purpose of this study was to investigate the correlation between topoisomerase II alpha (Topo II alpha) expression and the chemosensitivity to Topo II-targeting drugs in gynaecological carcinomas.
We analysed the expression of Topo II alpha, and then correlated this with the in vitro chemosensitivities of 43 gynaecological tumors using immunohistochemistry and a tetrazolium dye (MTT) assay.
There was a significant correlation between the Topo II alpha index (the number of positive cells per 100 cells: %) and the tumor cell growth inhibition rate in culture (I.R.: %) for doxorubicin and etoposide (r = 0.631, p < 0.001 and r = 0.645, p < 0.001, respectively). The I.Rs for doxorubicin and etoposide in endometrial carcinomas were lower than those in ovarian carcinomas [38.2 +/- 22.8 vs 54.6 +/- 29.8, 37.3 +/- 19.8 vs 59.3 +/- 30.6] (p < 0.05, respectively). Furthermore, the number of high Topo II alpha index (over 30%) tumors in the ovarian carcinoma cases was higher than that in the endometrial carcinoma cases (63.1% vs 45.8%, p < 0.05).
Our data suggest that the Topo II alpha index of a tumor is a reflection of its chemosensitivity to Topo II-targeting drugs. The use of this index may enable prediction of a clinical response to chemotherapy using Topo II-targeting drugs in gynaecological malignancies.
本研究旨在探讨拓扑异构酶IIα（Topo IIα）表达与妇科恶性肿瘤对拓扑异构酶II靶向药物的化疗敏感性之间的相关性。
我们分析了Topo IIα的表达情况，然后通过免疫组织化学和四氮唑盐（MTT）法将其与43例妇科肿瘤的体外化疗敏感性进行关联分析。
对于阿霉素和依托泊苷，Topo IIα指数（每100个细胞中的阳性细胞数：%）与培养中的肿瘤细胞生长抑制率（I.R.：%）之间存在显著相关性（分别为r = 0.631，p < 0.001和r = 0.645，p < 0.001）。子宫内膜癌中阿霉素和依托泊苷的I.R.低于卵巢癌[38.2±22.8对54.6±29.8，37.3±19.8对59.3±30.6]（p均<0.05）。此外，卵巢癌病例中Topo IIα指数高（超过30%）的肿瘤数量高于子宫内膜癌病例（63.1%对45.8%，p < 0.05）。
我们的数据表明肿瘤的Topo IIα指数反映了其对拓扑异构酶II靶向药物的化疗敏感性。使用该指数可能有助于预测妇科恶性肿瘤中使用拓扑异构酶II靶向药物化疗的临床反应。
